Amicus Therapeutics Stock News

Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 3,000 shares of the stock in a transaction dated Wednesday, December 22nd. The shares were sold at an average price of $11.70, for a total transaction of $35,100.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Shares of […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD)s share price traded up 3.3% on Monday . The company traded as high as $11.24 and last traded at $11.20. 63,264 shares changed hands during trading, a decline of 97% from the average session volume of 1,972,736 shares. The stock had previously closed at $10.84. A number of research analysts recently []

Amicus Therapeutics Inc. (NASDAQ:FOLD) shares, rose in value on Friday, 12/17/21, with the stock price up by 7.33% to the previous days close as strong demand from buyers drove the stock to $10.84. Actively observing the price movement in the last trading, the stock closed the session at $10.10, falling within a range of $9.98 Amicus Therapeutics Inc. (NASDAQ: FOLD) Is An Exciting Stock To Watch. Read More »

In the last trading session, 1.6 million shares of the Amicus Therapeutics Inc. (NASDAQ:FOLD) were traded, and its beta was 1.20. Most recently the company’s share price was $10.39, and it changed around -$0.07 or -0.67% from the last close, which brings the market valuation of the company to $2.94B. FOLD currently trades at a … It’s Easy To Bet On Amicus Therapeutics Inc. (NASDAQ: FOLD) For Economic Progress Over The Impending Months Read More »

ORLANDO, Fla. , Dec. 10, 2021 /PRNewswire/ -- Statewide leaders of Florida''s life sciences industry representing biopharmaceutical, medical technology, and digital health companies, globally recognized research universities, and some of the leading non-profit research institutes in the world united at the BioFlorida Annual Conference to celebrate the unprecedented progress, growth, and collaboration in science, business, and public policy and collaborate to spur future growth. " Florida has firmly established itself as a leading life science destination in the nation representing 6,700 establishments and research organizations that employ nearly 94,000 Floridians," said Nancy K. Bryan , President and CEO of BioFlorida. "Our strong foundation and sustained growth allowed our Florida -based companies, research organizations, universities, and health systems to diagnose, treat, and prevent COVID-19 while continuing to progress in other therapeutic areas. The Conference allowed our industry to celebrate these successes, identify the best practices, and apply it to areas like cancer, Alzheimer''s, and other diseases that impact our family, friends, and neighbors." The Conference explored topics ranging from new strategies in neurodegenerative diseases like Alzheimer''s, immuno-oncology, gene and cell therapy to diversity, equity, and inclusion to emerging trends and company successes in the various life science sectors led by CEOs and executive leadership from Florida -based companies.

In the last trading session, 2.16 million Amicus Therapeutics Inc. (NASDAQ:FOLD) shares changed hands as the companys beta touched 1.21. With the companys per share price at $11.21 changed hands at $0.59 or 5.56% during last session, the market valuation stood at $3.33B. FOLDs last price was a discount, traded about -126.49% off its 52-week Amicus Therapeutics Inc. (NASDAQ: FOLD) Could Soar To Much Higher Prices In Coming Months Read More »

Wells Fargo & Company MN lessened its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 21.0% during the second quarter, Holdings Channel reports. The institutional investor owned 528,167 shares of the biopharmaceutical companys stock after selling 140,754 shares during the quarter. Wells Fargo & Company MNs holdings in Amicus Therapeutics were worth $5,092,000 as of its []

These eight stocks could rebound nicely over the next year and beyond.

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned an average rating of Buy from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among []

PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) f

PHILADELPHIA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Applications (MAA) for AT-GAA, the Companys investigational two-component therapy for the treatment of Pompe disease. Validation of the application confirms the submission is accepted, and the EMAs centralized procedure with Committee for Medicinal Products for Human Use (CHMP)s assessment begins.

Complete study of the global Lysosomal Storage Disease (LSD) market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding